Intraindividual, randomized comparison of the macrocyclic contrast agents gadobutrol and gadoterate meglumine in breast magnetic resonance imaging.

Saved in:

Bibliographic Details
Title:	Intraindividual, randomized comparison of the macrocyclic contrast agents gadobutrol and gadoterate meglumine in breast magnetic resonance imaging.
Authors:	Fallenberg, Eva¹ eva.fallenberg@charite.de, Renz, Diane¹, Karle, Bettina², Schwenke, Carsten³, Ingod-Heppner, Barbara⁴, Reles, Angela⁵, Engelken, Florian⁶, Huppertz, Alexander⁷, Hamm, Bernd¹, Taupitz, Matthias⁷
Source:	European Radiology. Mar2015, Vol. 25 Issue 3, p837-849. 13p.
Subjects:	Magnetic resonance imaging, Breast cancer diagnosis, Tissue wounds, Diagnostic imaging research, Medical imaging systems
Abstract:	Objectives: To compare intraindividually two macrocyclic contrast agents - gadobutrol and gadoterate meglumine (Gd-DOTA) - for dynamic and quantitative assessment of relative enhancement (RE) in benign and malignant breast lesions. Methods: This was an ethically approved, prospective, single-centre, randomized, crossover study in 52 women with suspected breast lesions referred for magnetic resonance imaging (MRI). Each patient underwent one examination with gadobutrol and one with Gd-DOTA (0.1 mmol/kg BW) on a 1.5 T system 1 - 7 days apart. Dynamic, T1-weighted, 3D gradient echo sequences were acquired under identical conditions. Quantitative evaluation with at least three regions of interest (ROI) per lesion was performed. Primary endpoint was RE during the initial postcontrast phase after the first and second dynamic acquisition, and peak RE. All lesions were histologically proven; differences between the examinations were evaluated. Results: Forty-five patients with a total of 11 benign and 34 malignant lesions were assessed. Mean RE was significantly higher for gadobutrol than Gd-DOTA ( p < 0.0001). Gadobutrol showed significantly less washout (64.4 %) than Gd-DOTA (75.4 %) in malignant lesions ( p = 0.048) Conclusions: Gadobutrol has higher RE values compared with Gd-DOTA, whereas Gd-DOTA shows more marked washout in malignant lesions. This might improve the detection of breast lesions and influence the specificity of breast MRI-imaging. Key Points: • Contrast agents differ in terms of peak enhancement and postinitial contrast behaviour. • Gadobutrol results in greater peak RE in lesions, likely due to relaxivity. • Gd-DOTA shows more pronounced washout in postinitial contrast behaviour of malignant lesions. • Further investigations of the differences among GD-CM may improve sensitivity and specificity. [ABSTRACT FROM AUTHOR]
	Copyright of European Radiology is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	Engineering Source

Description
Abstract:	Objectives: To compare intraindividually two macrocyclic contrast agents - gadobutrol and gadoterate meglumine (Gd-DOTA) - for dynamic and quantitative assessment of relative enhancement (RE) in benign and malignant breast lesions. Methods: This was an ethically approved, prospective, single-centre, randomized, crossover study in 52 women with suspected breast lesions referred for magnetic resonance imaging (MRI). Each patient underwent one examination with gadobutrol and one with Gd-DOTA (0.1 mmol/kg BW) on a 1.5 T system 1 - 7 days apart. Dynamic, T1-weighted, 3D gradient echo sequences were acquired under identical conditions. Quantitative evaluation with at least three regions of interest (ROI) per lesion was performed. Primary endpoint was RE during the initial postcontrast phase after the first and second dynamic acquisition, and peak RE. All lesions were histologically proven; differences between the examinations were evaluated. Results: Forty-five patients with a total of 11 benign and 34 malignant lesions were assessed. Mean RE was significantly higher for gadobutrol than Gd-DOTA ( p < 0.0001). Gadobutrol showed significantly less washout (64.4 %) than Gd-DOTA (75.4 %) in malignant lesions ( p = 0.048) Conclusions: Gadobutrol has higher RE values compared with Gd-DOTA, whereas Gd-DOTA shows more marked washout in malignant lesions. This might improve the detection of breast lesions and influence the specificity of breast MRI-imaging. Key Points: • Contrast agents differ in terms of peak enhancement and postinitial contrast behaviour. • Gadobutrol results in greater peak RE in lesions, likely due to relaxivity. • Gd-DOTA shows more pronounced washout in postinitial contrast behaviour of malignant lesions. • Further investigations of the differences among GD-CM may improve sensitivity and specificity. [ABSTRACT FROM AUTHOR]
ISSN:	09387994
DOI:	10.1007/s00330-014-3426-0